研究伊朗人群中rs4962416和rs6465657与前列腺癌的关系

Q4 Pharmacology, Toxicology and Pharmaceutics
S. Angaji, Tannaz Hemmati, B. Beikzadeh, H. Alibeik, R. Roudi, B. Narouie
{"title":"研究伊朗人群中rs4962416和rs6465657与前列腺癌的关系","authors":"S. Angaji, Tannaz Hemmati, B. Beikzadeh, H. Alibeik, R. Roudi, B. Narouie","doi":"10.2174/1875692120666230816150545","DOIUrl":null,"url":null,"abstract":"\n\nProstate cancer is one of the most commonly diagnosed malignancies in the developed world. Despite other risk factors like age, diet, environment and the pathogenesis of prostate cancer, recent advances in molecular genetics suggest that genetic inheritance plays an important role in prostate cancer.\n\n\n\nWe attempted to analyze the association of SNPs rs4962416 and rs6465657 in the development of prostate cancer. A better understanding of the association of SNPs in prostate cancer susceptibility may improve risk prediction, improve precision mapping, and provide new insights into the underlying pathophysiology of prostate cancer. To date, no one has investigated these two SNPs in the Iranian populations, and according to the heterogeneity that exists, SNPs in communities should be examined separately.\n\n\n\nThis case-control study includes 82 people with prostate adenocarcinoma as cases and 96 people with benign prostatic hyperplasia (BPH) as controls. Genotyping of each participant was done by TETRA ARMS-PCR method and for statistical analysis chi-squared, Fisher’s exact logistic regression was used to find the SNPs associated with prostate cancer.\n\n\n\nThe frequency of the polymorphisms rs4962416 and rs6465657 in the prostate adenocarcinoma group was evaluated compared to the \nBPH control group (p-value < 0.05%) to choose the meaningful SNP.\n For rs4962416, we didn’t find any meaningful association with prostatic cancer (P=0.402) but for rs6465657 there was a significant difference between genotype frequency (P=0.001).\n\n\n\nrs6465657 polymorphism which is associated with prostate cancer, can be chosen as a biomarker for this cancer and there should be more investigation on this SNP as these results need to be confirmed in a larger population.\n","PeriodicalId":11056,"journal":{"name":"Current Pharmacogenomics and Personalized Medicine","volume":"32 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Investigating the association of rs4962416 and rs6465657 with prostate adenocarcinoma in the Iranian population..\",\"authors\":\"S. Angaji, Tannaz Hemmati, B. Beikzadeh, H. Alibeik, R. Roudi, B. Narouie\",\"doi\":\"10.2174/1875692120666230816150545\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n\\nProstate cancer is one of the most commonly diagnosed malignancies in the developed world. Despite other risk factors like age, diet, environment and the pathogenesis of prostate cancer, recent advances in molecular genetics suggest that genetic inheritance plays an important role in prostate cancer.\\n\\n\\n\\nWe attempted to analyze the association of SNPs rs4962416 and rs6465657 in the development of prostate cancer. A better understanding of the association of SNPs in prostate cancer susceptibility may improve risk prediction, improve precision mapping, and provide new insights into the underlying pathophysiology of prostate cancer. To date, no one has investigated these two SNPs in the Iranian populations, and according to the heterogeneity that exists, SNPs in communities should be examined separately.\\n\\n\\n\\nThis case-control study includes 82 people with prostate adenocarcinoma as cases and 96 people with benign prostatic hyperplasia (BPH) as controls. Genotyping of each participant was done by TETRA ARMS-PCR method and for statistical analysis chi-squared, Fisher’s exact logistic regression was used to find the SNPs associated with prostate cancer.\\n\\n\\n\\nThe frequency of the polymorphisms rs4962416 and rs6465657 in the prostate adenocarcinoma group was evaluated compared to the \\nBPH control group (p-value < 0.05%) to choose the meaningful SNP.\\n For rs4962416, we didn’t find any meaningful association with prostatic cancer (P=0.402) but for rs6465657 there was a significant difference between genotype frequency (P=0.001).\\n\\n\\n\\nrs6465657 polymorphism which is associated with prostate cancer, can be chosen as a biomarker for this cancer and there should be more investigation on this SNP as these results need to be confirmed in a larger population.\\n\",\"PeriodicalId\":11056,\"journal\":{\"name\":\"Current Pharmacogenomics and Personalized Medicine\",\"volume\":\"32 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-08-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Pharmacogenomics and Personalized Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/1875692120666230816150545\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Pharmacogenomics and Personalized Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1875692120666230816150545","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

摘要

前列腺癌是发达国家最常见的恶性肿瘤之一。除了年龄、饮食、环境和前列腺癌的发病机制等其他危险因素外,分子遗传学的最新进展表明,基因遗传在前列腺癌中起着重要作用。我们试图分析snp rs4962416和rs6465657在前列腺癌发展中的关联。更好地了解snp与前列腺癌易感性的关系可能会改善风险预测,提高精确定位,并为前列腺癌的潜在病理生理提供新的见解。到目前为止,还没有人在伊朗人群中调查过这两种snp,根据存在的异质性,应该分别检查社区中的snp。本病例对照研究包括82例前列腺癌患者和96例良性前列腺增生(BPH)患者作为对照。通过TETRA ARMS-PCR方法对每个参与者进行基因分型,统计学分析采用Fisher精确逻辑回归来寻找与前列腺癌相关的snp。比较前列腺癌组与BPH对照组rs4962416和rs6465657多态性的频率(p值< 0.05%),选择有意义的SNP。对于rs4962416,我们没有发现与前列腺癌有任何有意义的关联(P=0.402),但对于rs6465657,基因型频率之间存在显著差异(P=0.001)。rs6465657多态性与前列腺癌相关,可以选择作为前列腺癌的生物标志物,由于这些结果需要在更大的人群中得到证实,因此需要对该SNP进行更多的研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Investigating the association of rs4962416 and rs6465657 with prostate adenocarcinoma in the Iranian population..
Prostate cancer is one of the most commonly diagnosed malignancies in the developed world. Despite other risk factors like age, diet, environment and the pathogenesis of prostate cancer, recent advances in molecular genetics suggest that genetic inheritance plays an important role in prostate cancer. We attempted to analyze the association of SNPs rs4962416 and rs6465657 in the development of prostate cancer. A better understanding of the association of SNPs in prostate cancer susceptibility may improve risk prediction, improve precision mapping, and provide new insights into the underlying pathophysiology of prostate cancer. To date, no one has investigated these two SNPs in the Iranian populations, and according to the heterogeneity that exists, SNPs in communities should be examined separately. This case-control study includes 82 people with prostate adenocarcinoma as cases and 96 people with benign prostatic hyperplasia (BPH) as controls. Genotyping of each participant was done by TETRA ARMS-PCR method and for statistical analysis chi-squared, Fisher’s exact logistic regression was used to find the SNPs associated with prostate cancer. The frequency of the polymorphisms rs4962416 and rs6465657 in the prostate adenocarcinoma group was evaluated compared to the BPH control group (p-value < 0.05%) to choose the meaningful SNP. For rs4962416, we didn’t find any meaningful association with prostatic cancer (P=0.402) but for rs6465657 there was a significant difference between genotype frequency (P=0.001). rs6465657 polymorphism which is associated with prostate cancer, can be chosen as a biomarker for this cancer and there should be more investigation on this SNP as these results need to be confirmed in a larger population.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Current Pharmacogenomics and Personalized Medicine
Current Pharmacogenomics and Personalized Medicine Pharmacology, Toxicology and Pharmaceutics-Pharmacology
CiteScore
0.40
自引率
0.00%
发文量
11
期刊介绍: Current Pharmacogenomics and Personalized Medicine (Formerly ‘Current Pharmacogenomics’) Current Pharmacogenomics and Personalized Medicine (CPPM) is an international peer reviewed biomedical journal that publishes expert reviews, and state of the art analyses on all aspects of pharmacogenomics and personalized medicine under a single cover. The CPPM addresses the complex transdisciplinary challenges and promises emerging from the fusion of knowledge domains in therapeutics and diagnostics (i.e., theragnostics). The journal bears in mind the increasingly globalized nature of health research and services.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信